CVS Health wants to do much more than fill your prescription or jab your arm with an annual flu shot. The second-largest U.S. drugstore chain is buying Aetna, the third-largest health insurer, in order to push much deeper into customer care. The evolution won’t happen overnight, but in time, shoppers may find more clinics in…
Three Reasons Why CVS Would Want to Buy Health Insurer Aetna
A CVS-Aetna combination could create a health colossus that can reach deeper into the average customer’s life to manage care and cut costs, according to analysts who follow the companies. Drugstore chain and pharmacy benefits manager CVS Health Corp. is in talks to buy the nation’s third-largest insurer, Aetna Inc., according to a report Thursday…
Lilly Tops Street 3Q Forecasts, Considers Business Sale
Eli Lilly is weighing the sale of an animal health business that the drugmaker once touted as key in helping it overcome the loss of patent protection for some top-selling drugs. Lilly said Tuesday that alternatives for its Elanco Animal Health business also include an initial public offering or a merger. The drugmaker also might…
Drugmaker Lilly to Trim Workforce by Nearly 9 Percent
Eli Lilly will slash its global workforce by nearly 9 percent as the drugmaker closes some research sites and pushes to trim fixed costs. The Indianapolis company said Thursday it will cut about 3,500 positions, mostly through a voluntary retirement program in the United States. The insulin and cancer treatment maker employed 41,240 people worldwide…
Gilead to Pay $11.9B for Cancer Treatment Developer Kite
Gilead Sciences will pay $11.9 billion in cash to buy Kite Pharma and plant a stake in an emerging area of cancer treatments that train a patient’s immune cells to attack tumors. Kite’s portfolio of potential treatments includes one for the blood cancer lymphoma that could receive U.S. regulatory approval later this year. The Santa…
UnitedHealth 1Q Profit Soars as ACA Business Shrinks
How Do Insurers Decide What Medicines to Pay For?
Walgreens Slashes Offer for Rite Aid, Pushes Back Deadline
J&J Cautious in Outlook, Shops Diabetes Care
Johnson & Johnson edged above fourth-quarter profit expectations, helped by consumer goods and pharmaceutical growth, but the world’s biggest health care products company also gave Wall Street a softer-than-expected 2017 earnings forecast. The maker of Band-Aids and prescription drugs also said Tuesday it was taking another step in restructuring its medical device segment by shopping…
J&J Spends $30 Billion on Switzerland’s Actelion
Johnson & Johnson is buying Swiss pharmaceutical Actelion in a $30 billion deal that will boost its treatments for life-threatening high blood pressure conditions. The deal announced Thursday comes a little more than a month after J&J said it had ended talks to buy Actelion, and the Swiss company had said it was in discussions…
UnitedHealth Looks Beyond Insurance to Help Fuel 4Q Growth
Johnson & Johnson Cautious in Outlook, Shops Diabetes Care
Johnson & Johnson edged Wall Street profit expectations for the fourth quarter but announced a lower-than-expected 2017 forecast and said it would start shopping its diabetes care businesses. Johnson & Johnson said Tuesday that it would start seeking a possible sale, joint venture or operating partnerships for LifeScan Inc., Animas Corp. and Calibra Medical Inc.…
CVS to Sell Generic EpiPen Competitor at a 6th The Price
CVS is now selling a rival, generic version of Mylan’s EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to consumers. The drugstore chain says it will charge $109.99 for a two-pack of the authorized generic version…
Eli Lilly: Failed Study, Dimmed Hopes in Hunt for Alzheimer’s Treatment
A treatment for Alzheimer’s failed to slow mental decline in a widely anticipated study, ending hope that researchers at Eli Lilly had finally found a drug that does more to help those suffering from the fatal, mind-robbing disease. The pharmaceutical company’s shares plunged 14 percent Wednesday before markets opened. The drug, solanezumab, missed the study’s main goal when…
Walgreens Posts Strong 4Q Earns, But Delays Rite Aid Deal
Walgreens Boots Alliance earnings topped $1 billion during the fourth quarter, easily surpassing analyst expectations, but the drugstore giant also announced a delay in closing its latest megadeal. The company said Thursday that it expects to wrap up its $9.4-billion purchase of rival Rite Aid Corp. early next year, rather than by the end of…
UnitedHealth Raises 2016 Forecast, Trumps 3Q Expectations
UnitedHealth Group hiked its 2016 earnings forecast again after its profit swelled 23 percent to nearly $2 billion in the third quarter, helped by gains both in and outside its core insurance business. The nation’s biggest health insurer now expects adjusted, full-year earnings of about $8 per share, up from its previous forecast of $7.80…
A Front-Row Seat for the Drug Pricing Battle
Drugmaker Pfizer Decides Not to Break Up Business
Pfizer will not split into two publicly traded companies, a decision that, at least for now, ends Wall Street speculation over the drugmaker’s future. The company said Monday it believes it is best positioned to maximize shareholder value in its current form, but it reserves the right to split in the future if the situation changes.…
CVS Health Tops 2Q Profit Forecasts
Long-Time Lilly CEO Lechleiter to Retire in December
Eli Lilly Chairman and CEO John C. Lechleiter will retire in December after leading the drugmaker through a challenging period in which it lost U.S. patent protection for several top-selling products. The Indianapolis company says the president of its bio-medicines business, David A. Ricks, will replace Lechleiter as CEO in January and become board chairman…
Long-Time Lilly CEO Lechleiter to Retire in December
Eli Lilly Chairman and CEO John C. Lechleiter will retire in December after leading the drugmaker through a challenging period in which it lost U.S. patent protection for several top-selling products. The Indianapolis company says the president of its bio-medicines business, David A. Ricks, will replace Lechleiter as CEO in January and become board chairman…